RECOMBINANT IGF BINDING PROTEIN (IBP-1)

Abstract: An IGF binding protein which has the amino acid sequence (I), or an equivalent modification thereof, such as a glycosylated modification. Further is indicated a DNA-sequence, coding for the protein, an expression vector and a pharmaceutical preparation containing the protein. The protein is effective as a potentiator for the function of IGF-compounds.

Description: Recombinant IGF binding protein (IBP-1) The present invention relates to an Insulin-like Growth Factor Binding Protein, IBP-1, having a molecular weight of about 28 kD, derived from human placenta/endometrium, and equivalent modifications thereof. The invention further relates to a DNA-structure, coding for the IBP-1, expression vectors containing this DNA- structure and procaryotic or eucaryotic cells comprising such a vector. The invention still further relates to pharmaceutical preparations comprising IBP-1. IGF or Insulin like Growth Factor is synonymous with somatomedins. The family of somatomedins are members of a group of polypeptides derived from the insulin gene. The gene products include insulin, insuline-like growth factor (IGF)I and II, relaxin and the B-unit of nerve growth factor (NGF) (Rinderknecht and Humbel, 1978a; Rinderknecht and Humbel, 1978b; Bradshaw 1978; Isaacs et al,, 1978). IGF elicits classical insulin effects on all target tissues of insulin, i.e. IGF increases glucose metabolism of adipose tissue and stimulates lipid, glycogen, and protein synthesis. IGF also stimulates DNA synthesis in certain cell types. This feature reflects the capacity of IGFs to induce cell proliferation and promote organ growth _in vivo. Furthermore, IGF acts on differentiation of mesenchymal cells (Froesch et al., 1985). IGF-I and IGF-II are unique in that they are complexed to specific binding proteins in plasma (Smith, 1984). At least two different binding proteins have been iden- tified in adult human serum, namely (1) binding protein 53 (BP-53) a GH dependent binding protein, believed to be derived from the 150 kD complex which carries most of the endogenous IGF peptides, (2) IBP-1, an IGF binding protein of about 30-40 kD which is tissue specifically expressed in endometrium and liver and accounts for most of the unsaturable binding sites in plasma. While the 53 kD-binding protein is under GH control the 30-40 kD species appears to be expressed in a GH independent way. The lower molecular weight binding protein was initially identified in human a niotic fluid and has been puri¬ fied and characterized (Chochinov et al., 1977; Drop et al., 1979; Drop et al., 1982). This 30-40 kD IGF binding protein appears to be identical to binding proteins that have been purified from human serum and the human hepatoma cell line, HEPG2 (Drop et al., 1984a; Povoa et al., 1984; Povoa et al. , 1985). Povoa et al showed that the NH^-terminal amino acid sequence of the binding protein found in amniotic fluid and from the HEPG2 cell line are similar (Povoa et al., 1985). Placental protein PP12, a protein originally isolated from human placenta, was found to bind IGF as well as to have an identical NH_—terminal amino acid sequence (Koistinen et al., 1986). As to the biological function of IGF-binding protein both stimulatory and inhibitory effects have been des¬ cribed. Stimulatory effects of IGF-binding protein has been shown in at least two cases. Clemmons et al (1986) showed increased binding to fibroblast and smooth muscle cell surface receptors of IGF in complex with its bind¬ ing protein. Inhibitory effects of IGF-binding protein on various IGF actions in vitro, including stimulation of glucose transport by adipocytes, sulphate incorporation by chondrocytes and thymidine incorporation in fibroblasts have been described ( Zapf et al., 1979; Drop et al., 1979; Ooi et al., 1986). In addition, inhibitory effects of IGF-binding proteins on growth factor mediated mitogen activity in normal cells (cartilage assay, Drop, thesis, 1983). According to the invention, the IGF-binding protein has the following amino acid sequence: Ala-Pro-Trp-Gln-Cys-Ala-Pro-Cys-Ser-Ala-Glu-Lys-Leu-Ala- Leu-Cys-Pro-Pro-Val-Ser-Ala-Ser-Cys-Ser-Glu-Val-Thr-Arg- Ser-Ala-Gly-Cys-Gly-Cys-Cys-Pro-Met-Cys-Ala-Leu-Pro-Leu- Gly-Ala-Ala-Cys-Gly-Val-Ala-Thr-Ala-Arg-Cys-Ala-Arg-Gly- Leu-Ser-Cys-Arg-Ala-Leu-Pro-Gly-Glu-Gln-Gln-Pro-Leu-His- Ala-Leu-Thr-Arg-Gly-Gln-Gly-Ala-Cys-Val-Gln-Glu-Ser-Asp- Ala-Ser-Ala-Pro-His-Ala-Ala-Glu-Ala-Gly-Ser-Pro-Glu-Ser- Pro-Glu-Ser-Thr-Glu-Ile-Thr-Glu-Glu-Glu-Leu-Leu-Asp-Asn- Phe-His-Leu-Met-Ala-Pro-Ser-Glu-Glu-Asp-His-Ser-Ile-Leu- Trp-Asp-Ala-Ile-Ser-Thr-Tyr-Asp-Gly-Ser-Lys-Ala-Leu-His- Val-Thr-Asn-Ile-Lys-Lys-Trp-Lys-Glu-Pro-Cys-Arg-Ile-Glu- Leu-Tyr-Arg-Val-Val-Glu-Ser-Leu-Ala-Lys-Ala-Gln-Glu-Thr- Ser-Gly-Glu-Glu-Ile-Ser-Lys-Phe-Tyr-Leu-Pro-Asn-Cys-Asn- Lys-Asn-Gly-Phe-Tyr-His-Ser-Arg-Gln-Cys-Glu-Thr-Ser-Met- Asp-Gly-Glu-Ala-Gly-Leu-Cys-Trp-Cys-Val-Tyr-Phe-Trp-Asn- Gly-Lys-Arg-Ile-Pro-Gly-Ser-Pro-Glu-Ile-Arg-Gly-Asp-Pro- Asn-Cys-Gln-Met-Tyr-Phe-Asn-Val-Gln-Asn The complete nucleotide sequence of the corresponding cDNA sequence was shown to have the structure depicted in claim 5. The protein according to the invention may be used as an effective potentiator for the functioning of somatomedins. The effect can be mediated through the firm binding between the somatomedins and their binding proteins under physiological conditions. Such complexed somatomedins together with their binding proteins are protected against undue proteolysis, causing a signifi¬ cant increase of the biological haif life of somatome¬ dins. Furthermore, this IGF-binding protein or modifica¬ tions hereof might function as a potent carrier of IGF to its local sites of action. The studies of Clemmons (1986) demonstrate the potential usefulness of this IGF-1 binding protein or modifications hereof in fertilization and in potentiation of growth of connective tissue and muscle cells in tissue repair. As IGF-binding protein, or modifications thereof, such as alpha 1 PEG, are the major secretory soluble protein of decidual cells of the endometirum, IBP-1 may have an important function in restricting trophoblast invasion into the endometrium during placental development. Furthermore, the inhibitory function of IBP-1 in cellular proliferation assays and the unexpected direct inhibitory- effect of IBP-1 on the oestrogen response on certain cancer cells make IBP-1 or modifications hereof a poten- ' tial anticancer reagent with local growth inhibitory effect. The invention is explained more in detail in the follow¬ ing description with reference to the drawing, in which fig. 1 illustrates a restriction map and sequence stra¬ tegy for human 28 kD IGF binding protein cDNA clones, fig. 2 shows the nucleotide and deducted amino acid sequence of human IGF binding protein where differences between the placental cDNA sequence and the liver cDNA sequence are shown in parenthesis, and fig. 3 represents an SDS/PAGE analysis of culture media of COS-1 cells transfected with pSV19, pSV , pSV4Inv and untransfected COS-1 cells. The cDNA encoding IGF-BP was obtained by screening a human placental and a human hepatoma (HEPG-2) cDNA- expression library with a polyclonal antibody to human amniotic fluid binding protein (Drop et al., 1984a). Restriction analysis indicated that the clones isolated from the placenta library and the clones isolated from the HEPG2 library were colinear (fig. 1), supporting their candidacy as IGF binding protein clones. The composite restriction map is shown at the top of the figure 1. A putative leader sequence is shown in front of the open box representing translated regions. Each arrow shows the direction and extend of sequencing by chain termination. Four different clones are aligned. p4 and pi9 originate from the placental cDNA library, while wβl and w85 originate from the HEPG2 cDNA library, (E = EcoRI, P = Pstl, B = BamHI, H = Hindu, S = Sstl, X = Xbal, N = Ncol) . The complete nucleotide sequence of the cDNA insert of one of the clones isolated (pi9) was determined. The 1421 nucleotide sequence shown in fig. 2 contains a 5* untranslated region of 52 nucleotides followed by an ATG codon and an open reading frame of 776 nucleo¬ tides. The potential initiation codon is flanked by 5 sequences matching Kozak's criteria for an initiation codon (Kozak, 1986). At the 3' end the open reading frame is flanked by a translation termination codon (TGA) and a 569 nucleotides long 3' untranslated se¬ quence. The open reading frame in cDNA clone pi9 has a coding capacity for a protein of 259 residues also shown in figure 2 (by the one-letter code), with a calculated Mw of 28,172 daltons. The initiation methione is the first amino acid of a 24-residue highly hydrophobic peptide sequence (underlined), representing the sequence of a putative signal sequence necessary for transfer of .the nascent polypeptide sequence into the membranes of the endoplas atic reticulim. A favourable signal peptidase cleavage site (ala-gly) occurs immediately N-terminally of the alanine residue at pos +1 (von Heijne, 1987). The NH_-terminus of the predicted mature protein is identical to the chemically determined NH_- terminus described for the IGF-binding protein isolated both from amniotic fluid (Povoa et al., 1984), and from the HEPG2 cell line (Povoa et al., 1985) and from serum (Baxter et al., 1987). Omitting the signal peptide sequence, the M of this gene product is predicted to be 2,350 daltons. The M of serum IGF binding protein is about 28,000 daltons (Baxter et al., 1987). The difference is believed to be accounted for by glycosylation of the IGF binding protein (Bohn et al. , 1980; Koistinen et al., 1986). The amino acid sequence did not disclose N-linked glyco¬ sylation sites (N-T, N-S). However, at least five po¬ tential O-linked glycosylation sites were found in the NH 2 ~terminal .of the molecule. A RGD sequence in the COOH terminal part of the IBP-1 protein has been found. Such a short sequence is considered to be im¬ portant for cellular attachment of matrix proteins, such as fibronectin, vitronectin and von Willebrand factor, to receptors of the integrin family. Amino acid homology with other known proteins and pep- tides were determined by searching the NFBR data base, version 12.0 and 26.0. The IGF-BP protein did not show any significant protein homology, indicating that IGF-BP is a unique protein. In particular, comparison of amino acid sequence of IGF-I, IGF-II, Insulin, Type I IGF receptor and the type II IGF receptor amino acid se- quences revealed no homologous domains. In addition, no homology was found with the reported NH 2 ~terminal amino acid sequence for the high molecular weight IGF binding protein (Baxter et al., 1986). It was further possible to express IBP-1 in mammalian cells. Expression vectors, pSV19, pSV4 and pSV4Inv were constructed by inserting the full length clones p4 and pl9 in the expression vector pSV328. The vectors pSV4, pSVl9 and pSV4Inv, in which the cDNA insert is in 3' - 5' orientation, were transfected to COS-1 cells. By use of SDS/PAGE analysis cell culture media from COS-1 cells transfected with pSV19 (lane A), pSV4 (lane B), and amniotic fluid (lane C) were analysed. The IGF binding proteins were made visible by immuno staining as described for the screening of the cDNA libraries. In culture media of pSV4 and pSV19 transfected COS-1 cells in which the gene is in the correct orientation a protein of 32 kD being immunologically indistinguish¬ able from the IGF binding protein from amniotic fluid (fig. 3) was detected. In all culture media a band was visible which reacted with the 35 kD SMBP antibody but which was absent in the culture medium from untrans- fected COS-1 cells. Although IBP-1 successfully has been expressed in COS-1 cells the lack of N-linked glycosylation sites in the putative protein also favour expression in yeast and bacteria to increase the IBP-1 production to be used in a variety of therapeutic compositions. The invention provides therapeutic compositions compris¬ ing IBP-1 or derivatives thereof and pharmacologically acceptable excipients. Such compositions including the IGF-binding protein or derivatives hereof according to this invention have many therapeutic uses involving the physiological functions of somatomedins. The IGF-binding protein of the invention may be formu¬ lated as pharmaceutical preparations comprising the IGF-binding protein of the invention together with the usual excipients. Pharmaceutical preparations accord¬ ing to the invention may be in the form of suspension or solutions for parentheral administration, e.g. i.v., s.c, i.m. , implants, subcutaneous or interveneous administration or administration through the mucosa, e.g. oral, nasal, buccal, sublingual or rectal admini¬ stration or transdermal administration. For example in cases where somatomedins have toube transported to specific target tissues in a way where the physiological halflife of the somatomedins has to be increased by complexing IBP-1 described in this invention to IGF-1 and IGF-2. In accordance with this invention a slow release of active IGF-1 or 2 from such complexes would ascertain a constant level of somatomedins either locally or systemically dependent upon the way of administration. IBP-1 describes in this invention hereby abolishes the potent mitogenic effect of the somatomedins that administrated in high dosis, i.e. intra venously, would cause unwanted local cellular proliferations in a variety of cells like fibroblasts, muscle cells and endothelial cells. However, the IBP-1 described by this invention admini- stred together with IGF-1, IGF-2 and other growth fac¬ tors or formulated as common preparations for topical use (such as PDGF, EGF, FGF, TGFalpha or TGFbetha) employed in therapeutical devices to be used in healing of wounds or in treatment of oeteoporosis and in healing of bones might be valuable for a steady and controlled release of the somatomedins in such therapeutical de¬ vices. Such preparations may optionally be administred in the form of combination preparations e.g. comprising IBP-1 and IGF-1, IBP-1 and IGF-2 or IBP-1, IGF-1 and IGF-2. In general, IBP-1 according to this invention might turn out to exhibit a potent regulatory function in the release of IGF-1 and/or IGF-2 in future treatment of injuries or other malfunctions that requires increased IGF-1 and/or IGF-1 levels. On the other hand IBP-1 or derivatives thereof according to this invention might be useful in therapy of the proliferation of certain cancers characterized by pro¬ ducing somatomedins in high amounts thus inhibiting the autocrine/paracrine physiological stimulation of unwanted cellular proliferation in cancers like chondro- sarcomas, fibrosarcomas, and mammacarcinomas. Furthermore, the IBP-1 or derivatives hereof described in this invention is useful for the production of anti¬ bodies. Such mono- or polyclonal antibodies are suitable for developing immunological methods like immunohisto- chemical analysis of IBP-1 in tissues and for developing E ISA for IBP-1 quantitation. Such ELISA will prove valuable for early screening the levels of IBP-1 in patients with altered IGF-1 and 2 levels. Pharmaceutical preparations of this invention for s.c. and i.m. administration can be prepared by mixing the following constituents: IBP-1 and derivatives thereof together with IGF-1, IGF-2 and other growth factors, an isotonic agent, a buffer, a preservative and water. After mixing the pH value of the preparation is, if necessary, adjusted to pH = 7.3. Examples of preservatives: phenol and m-cresol. Examples of an isotonic agent: sodium chloride and glycerol. Example of buffer is sodium phosphate. Pharmaceutical preparations of this invention for trans- mucosal administration can be prepared by mixing the following constituents: IBP-1 and derivatives thereof, together with IGF-1, IGF-2 and other growth factors, a buffer, an isotonic agent, a preservative, an absorp¬ tion promotor and a vehicle e.g. water, cellulose, water-soluble cellulose alkylethers, crystalline cellu¬ lose, water-soluble polyacrylates or mixtures thereof. Pharmaceutical preparations of this invention for trans- dermal administration can be prepared by mixing the following constituents: IBP-1 and derivatives thereof together with IGF-1, IGF-2 and other growth factors, an isotonic agent, a preservative and a vehicle e.g. a hydrophilic gel of water-soluble cellulose alkyl- ethers. This invention is further explained in the following working example describing the isolation and charac¬ terization of IBP-1. EXAMPLE Screening the Lambda gtll Expression Library A human placenta cDNA library in lambda gtll and a cDNA library of the human hepatoma cell line HEPG2 were screened with a polyclonal antibody to human amnio¬ tic fluid binding protein according to the procedure described by Young and Davis (Young and Davis, 1982). Rabbit antibody to 35 kD somatomedin binding protein SMBP isolated from human amniotic fluid was produced and purified as described by Drop et al., 1984a. The antibody was absorbed against E.coli Y1090 and lambda gtll proteins by incubating with nitrocellulose filters that had been lifted from confluent lysis plates of E.coli Y1090/lambda gtll induced with 10 mM isopropyl beta-d-thiogalacopyranoside (IPTG). The antibody was further absorbed against human serum albumin immobilized on nitrocellulose filters. Approximately 4 x 10 clones of the placental library were screened and about 0.5 5 4 x 10 of the HPEG2 library. 3-5 x 10 plaque forming units per 150 mm Petri dish were plated on a lawn of Y1090 bacteria and incubated. After 2 hr incubation the plates were covered with nitrocellulose filters (Millipore HATF) that had been saturated with 10 mM IPTG. The plates were incubated at 37°C for 2-2.5 hrs. The filters were removed, washed with Tris-buffered saline (TBS; 10 mM Tris/HCl, pH 7.5/150 mM NaCl ) at room temperature and incubated with 3% BSA in TBS for 30 min. at room temperature. Partly purified rabbit polyclonal 35 kD SMBP antibody diluted 1:125 was added to 3% BSA in TBS plus 0.02% azide, and the filters were incubated overnight at 4°C. The filters were washed and incubated for 60 min. at room temperature with horse-radish peroxydase conjugated goat anti-rabbit IgG (Tago) diluted 1:200 in 3% BSA in TBS. The filters were washed and stained with amidophenyl and napthol AS-MX phosphate in 0.2 M Tris/HCl, pH 9.2, 10 mM MgCl- at room temperature. Positive phages were isolated and DNA was isolated by standard methods (Maniatis et al., 1982). About 33 plaques strongly cross-reacting with the polyclonal antibody were identified in the placenta and HEPG2 cDNA library. Following re-screening inserts varying in size between 0.9-1.5 Kb were isolated and subcloned in the vector PTZ19 from Pharmacia. All isolated clones showed cross-hybridization in a Southern blot except one clone from the placenta library and the 5 weakly hybridizing clones from the HEPG2 library. DNA was digested with various restriction endonucleases (BRL, NEN, Boehringer) according to the suppliers direc¬ tions, electrophoresed in 0.8% agarose, and transferred to nitrocellulose filters according to the method of southern (Southern, 1975). mRNA was denaturated with dimethylsulfozide (DMSO) and glyoxal, subjected to electrophoresis in 1% agarose and transferred to nitro¬ cellulose filters (Millipore HFTF). Restriction fragments were subcloned in the vectors PTZ18 or PTZ19 (Pharmacia) and sequenced according to the chain termination method (Sanger et al., 1977). In regions which lacked convenient restriction sites, appropriate clones were generated by Bal 31 nuclease digestion. Transfection of COS-1 Cells The full length cDNA clones p4 and pl9 were subcloned in the EcoRl site of pSV328, which expressed cloned inserts using the simian virus 40 (SV40) early promotor (Van Heuvel et al., 1986). A DEAE-dextran procedure (McCuthchan & Pagano, 1986) followed by treatment with 100 ,uM chloroquine in Dulbecco's MEM (DMEM) for 4 hrs was used to transfect COS-1 cells (Gluzman, 1981). After this treatment the cells were grown 24 hrs with DMEM plus 5% foetal calf serum. Medium was removed after 72 hrs, and the cells were washed extensively with DMEM and incubated for 72 hrs with DMEM without serum. Production of 32 kD binding protein in culture media was determined using 35 kD SMBP antibody. Purification of IBP-1 Proteins from amniotic fluid or from conditioned media were precipitated with ammonium sulphate at a final concentration of 35%. Following centrifugation the supernatant was brought to 50% ammonium sulphate. The pellet was dissolved in 45% ammonium sulphate and the final pellet was dissolved in 50 mM Tris HC1 , pH 7.5 for further purification and characterization. The dissolved ammonium sulphate precipitate was further purified by reverse phase chromatography on C, R . Follow¬ ing washings with 50 mM Tris-HCl, pH 7.5 and Tris HC1 , pH 7.5 in 50% methanol the pure IBP-1 was eluted from the column with Tris-HCl, pH 7.5 in 65% methanol. The IBP-1 was precipitated overnight in a 7% Trichloro- acetic-acid solution. The precipitate was dissolved in 20 mM Tris-HCl, pH 7.5, lyophilized and storred at -r 20°C. Characterization of purified IBP-1 IBP-1 binds both IGF-1 and IGF-2 with approximately the same specificity when measured in binding assays with | 125 I|IGF-1 and | 125 l|lGF-2 with or without excess of cold iGF-1 or IGF-2. The specificity of IBP-1 reaction was tested in similar assays employing such competition assays and in assays in which IBP-1 - IGF binding was visualized through the specific reaction of antibody against IBP-1. In such assays IBP-1 did only react with IGF«1 and IGF-2 but not with closely related com¬ pounds like insulin, proinsulin or truncated forms thereof. The biological effects of purified samples if IBP-1 were tested in in vitro mitogenicity tests employing 3 H-thymidin incorporation into a MCF-7 mamma carcinoma cell line. The stimulatory effect of both IGF-1 and IGF-2 on cell proliferation was inhibited by IBP-1 in a dose dependent way. The effect of IBP-1 on IGF-2 dependent cell proliferation was more pronounced than that of the effect of IBF-1. Furthermore, in an assay employing j S|-Methionin incorporation into cartillage the stimulatory effect of IGF-1 and IGF-2 was abolished by IBP in the low ng range. Examples of pharmaceutical preparations: EXAMPLE 1 25 ng IBP-1 10 ng IGF-1 0.7% NaCl 1/75M sodiumphosphate water ad 1 ml The calculated amounts of IBP-1 and IGF-1 were dis¬ solved and diluted in phosphate buffer containing NaCl. The pH was adjusted to 7.3-7.4. EXAMPLE 2 25 ng IBP-1 10 ng IGF-2 1.6% glycerin 1/75M sodiumphosphate 0.01% benzalconiumchlorid 0.05% sodiumedetat water ad 1 ml The calculated amounts of IBP-1 and IGF-2 were dis¬ solved and diluted in phosphate buffer containing gly¬ cerin, benzalconiumchlorid and sodiumedetat. The pH was adjusted to 7.4 EXAMPLE 3 25 ng IBP-1 10 ng IGF-1 10 ng IGF-2 5% hydroxyethylcellulose 0.9% benzylalcohol 1/75M phosphate buffer water ad 1 ml The gel is prepared by mixing hydroxyethylcellulose with the waterphase containing IBP-1, IGF-1 and IGF-2.

Claims: P a t e n t C l a i m s 1. An IGF binding protein, comprising the following amino acid sequence: A-P-W-Q-C-A-P-C-S-A-E-K-L-A-L-C-P-P-V-S-A-S-C-S-E-V-T-R-S-A- G-C- ^-C-C-PH4 -A-L-P-L-G-A-A-C-G-V-A-T-A-R--C-A-R-G-L-S-C-R- A-L-P-G-E-^3-Q-P-L-H-A-L-T-R-G-Q-G-A-C-V-Q-E-S-D-A-S-A-P-H-A- A-E-A-G-S-P-E-S-P-E-S-T-E-I-T-E-E-E-L-L-D-N-F-H-L-M-A-P-S-E- E-D-H-S-I-L-W-D-A-I-S-T-Y-D-G-S-K-A-L-H-V-T-N-I-K-K-W-E-P-C- R-I-E-L-Y-R-V-V-E-S-L-A-K-A-Q-E-T-S-G-E-E-I-S-K-F-Y-L-P-N-C- N-K-N-G-F-Y-H-S-R-^-C-E-T-S-M-D- E-A-G-LH-W-C-V-Y-P-W-N-G- K-R-I-P-G-S-P-E-I-R-G-D-P-N-C-Q-M-Y-F-N-V-Q-N- or an equivalent modification thereof. 2. A glycosylated modification of the protein according to claim 1. 3. An IGF binding protein according to claim 2, in which one or more hydroxy groups are glycosylated. 4. A DNA sequence, coding for the IGF binding protein as defined in claim 1. 5. A cDNA sequence according to claim 4 in which the coding strand includes the following structure: 1 GGGCGGGC A C AGCCAGAGAG CATCGGCCCC TGTCTGCTGC TCGCGCCTGG 51 d A TGlrC GA GGTCCCCGTT GCTCGCGTCT GGCTGGTACT GCTCCTGCTG 101 ACTGTCCAGG TCGGCGTGAC AGCCGGCGCT CCGTGGCAGT GCGCGCCCTG 151 CTCCGCCGAG AAGCTCGCGC TCTGCCCGCC GGTGTCCGCC TCGTGCTCGG 201 AGGTCACCCG GTCCGCCGGC TGCGGCTGTT GCCCGATGTG CGCCCTGCCT 251 CTGGGCGCCG CGTGCGGCGT GGCGACTGCA CGCTGCGCCC GGGGACTCAG 301 TTGCCGCGCG CTGCCGGGGG AGCAGCAACC TCTGCACGCC CTCACCCGCG 351 GCCAAGGCGC CTGCGTGCAG GAGTCTGACG CCTCCGCTCC CCATGCTGCA 401 GAGGCAGGGA GCCCTGAAAS CCCAGAGAGC ACGGAGATAA CTGAGGAGGA 451 GCTCCTGGAT AATTTCCATC TGATGGCCCC TTCTGAAGAG GATCATTCCA 501 TCCTTTGGGA CGCCATCAGT ACCTATGATG GCTCGAAGGC TCTCCATGTC 551 ACCAACATCA A A ATGG A GGAGCCCTGC- CGAATAGAAC TCTACAGAGT 601 CGTAGAGAGT TTAGCCAAGG CACAGGAGAC ATCAGGAGAA GAAATTTCCA 651 AATTTTACCT GCCAAACTGC AACAAGAATG GATTTTATCA CAGCAGACAG 701 TGTGAGACAT CCATGGATGG AGAGGCGGGA CTCTGCTGGT GCGTCTACCC 751 TTGGAATGGG AAGAGGATCC CTGGGTCTCC AGAGATCAGG GGAGACCCCA 301 ACTGCCAGAT GTATTTTAAT GTACAAAAcfr GA&ACCAGAT GAAATAATGT S51 TCTGTCACGT GAAATATTTA AGTA.TATAGT AT TTTATAC TCTAGAACAT 901 GCACATTTAT ATATATGTAT ATGTATATAT ATATAGTAAC TACTTCTTAT 951 ACTCCATACA TAACTTGATA TAGAAAGCTG TTTATTTATT CACTGTAAGT 1001 TTATTTTTTC TACACAGT A AAACTTGTAC TATGTTAATA ACTTGTCCTA 1051 TGTCAATTTG TATATCATGA AACACTTCTC ATCATATTGT ATGTAAGT 1101 TTGCATTTCT GCTCTTCCAA AGCTCCTGCG TCTGTTTTTA AAGAGCATGG 1151 AAAAATACTG CCTAGAAAAT GCAAAATGAA ATAAGAGAGA GTAGTTTTTC 1201 AGCTAGTTTG AAGGAGGAC3 GTTAACTTGT ATATTCCACC ATTCACATTT 1251 GATGTACATG TGTAGGGAAA GTTAAAAGTG TTGATTACAT AATCAAAGCT 1301 ACCTGTGGTG ATAGTTGCCA CCTGTT A A TGTACACTGG ATATGTTGTT 1351 AAAC CGTGT CTATAATGG AACATTTACIA I A—TAAA1*TATTC TGCATGGA 1401 AAAA AAAAA AA AAAA AAA.AA 6. An expression vector, containing the DNA sequence defined in claim 4 or 5. 7. The expression vector pSV19'. 8. The expression vector pSV4. 9. A cell line or a microorganism, comprising an ex¬ pression vector in accordance with claims 6, 7 or 8. 10. A pharmaceutical preparation, comprising the binding protein defined in any of the claims 1-3. LITERATURE: 1. Baxter R.C., Martin J.L., Tyler M.I., Howden, M.E.H. Growth hormone-dependent insulin-like growth factor (IGF) binding protein from human plasma differs from other human IGF binding proteins. a. Biochem. Biophys. Res. Communun. 1986: 139: 1256-1261. 2. Bohn H. , Kraus W. Isolierung und Charakterisierung eines neuen plaszentaspezifischen Proteins (PP12). Arch. Gynecol. 1980: 229-279 3. Bradshaw R.A. Nerve growth factor. Annu. Rev. Bio¬ chem. 1978: 47: 191-216. 4. Clemmons D.R. , Elgin R.G. , Han V.K.M., Casella S.J., D'Ercole A.J., Van Wyk J.J. Cultured fibroblast monolayers secrete a protein that alters the cellular binding of somatomedin-C/insulin-like growth factor I. J. Clin. Invest. 1986: 77: 1548-1556. 5. De Vroede M.A. , Tseng, L.Y.H., Katsoyannis P.G., Nissiev S.P., Rechler M.M. Modulation of insulin-like growth factor I binding to human fibroblast monolayer cultures by insulin-like growth factor carrier proteins released to the incubation media. J. Clin. Invest. 1986: 77: 602-613. 6. Drop S.L.S., Valiquette G. , Guyda H.J., Corvol M.T., Posner B.I. Partial purification and charac¬ terization of a binding protein for insulin-like activity (ILAs) in human amniotic fluid: a possible inhibitor of insulin-like activity. Acta. Endocrinol. (Copenh.) 1979) 90: 505-5118. 7. Drop S., Kortleve D. , Guyda H. Isolation of a soma- tomedin binding protein in human amniotic fluid: development of a radioimmunoassay. Pediatr. Res. 1982: 16: 890894. 8. Drop S.L.S., Kortleve D. . , Guyda H.J. Isolation of a somatomedin-binding protein from preterm amnio¬ tic fluid. Development of a radioimmunoassay. J. Clin. Endocrinol. Metab. 1984a: 59: 899-907. 9. Elgin R.G. , Busby Jr. W.H. , Clemmons D.R. An insulin¬ like growth factor (IGF) binding protein enhances the biologic response to -IGF-I. Proc. Natl. Acad. Sci. USA 1987: 84: 3254-3258. 10. Froesch E.R. Schmid C, Schwander J. , Zapf J. Actions of insulin-like growth factor. Ann. Rev. Physiol. 1985: 47: 443-467. 11. Heijne G. von. A new method for predicting signal sequence cleavage sites. Nucleic. Acid. Research 1986: 14: 714-722. 12. Isaacs N., James R. , Niall H. et al. Relaxin and its structural relationship to insulin. Nature 1978: 271: 278-281. 13. Koistinen R. , Kalkkinen N. , Huhtala M.L. , Seppala M. , Bohn H. , Rutanen E.M. Placental protein 12 is a decidual protein that binds somatomedin and has an identical N-terminal amino acid sequence with somatomedin-binding protein from human amniotic fluid. Endocrinology 1986: 118: 1375-1378. 14. Kozak M. Influences of mRNA secondary structure on initiation by eukaryotic ribosomes. Proc. Natl. Acad. Sci. USA 1986: 83: 2850-2854. 15. Maniatis T., Fritsch E.F., Sambrook J. ed. Molecular cloning: a laboratory manual. Cold Spring Harbor Laboratory 1982. 16. Povoa G., Enberg G. , Jδrnvall H. , Hall K. Isolation and characterization of a somatomedin-binding protein from mid-term human amniotic fluid. a. Eur. J. Biochem. 1984: 144: 199-204. 17. Povoa G. , Isaksson M. , Jδrnvall H. , Hall K. The somatomedin-binding protein isolated from a human hepatoma cell line is identical to the human amniotic fluid somatomedin-binding protein. Biochem. Biophys. Res. Commun. 1985: 128: 1071-1078. 18. Rinderknecht E., Humbel R.E. The amino acid sequence of human insulin-like growth factor I and its struc¬ tural homology with proinsulin. J. Biol . Chem. 1978a: 253: 2769-2776. 19. Rinderknecht E., Humbel R.E. Primary structure of human insulin-like growth factor II. FEBS Lett. 1978b: 89: 283-286. 20. Sanger F., Nicklan A.R., Coulson J. DNA sequencing with chain-terminating inhibitor. Proc. Natl. Acad. Sci. 1977: 74: 5463. 21. Smith G.L. Somatomedin carrier proteins. Mol. Cell. Endocrinal. 1984: 34: 85-89. 22. Southern E. Detection of specific sequences among DNA fragments separated by gelelectrophoresis. J. Mol. Biol. 1975: 98: 503. 23. Young R.A. , Davis R.W. Efficient isolation of genes by using antibody probes. Proc. Natl. Acad. Sci. USA 1983: 80: 1194-1198. 24. Gluzman Y. , SV40-transformed simian cells support the replication of early SV40 mutants, Cell., 23 (1) 175-82, 1981, Jan/IMD-8108. 25. McCutchan J.H. , Pagano J.S., Enchancement of the infectivity of simian virus 40 deoxyribonucleic acid with diethylaminoethyl-dextran, J. Natl. Cancer Inst., 41 (2) 351-7, Aug. 68/IMD-6810. 26. Van Heuvel M., Bosveld I.J., Mooren A.A. , Trapman J., Zwarthoff E.C., Properties of natural and hybrid murine alpha interferons, J. Gen. Virol., 67 (Pt 10) 2215-22, 1986 Oct/IMD-8701. 27. Zapf j., Schoenle E«, Jagers G., Sand I., Grϋnwald J. , Froesch E.R., Inhibition of the action of non- suppressible insulin-like activity on isolated fat cells by binding to its carrier protein * J. Clin. Invest. 1979: 63, 1077-1084. 28. Baxter R.C., Martin J.L. , Binding proteins for insulin-like growth factors in adult rat serum. Comparison with other human and rat binding pro¬ teins. Biochem. Biophys. Res. Commun. 1987: 147, 408. 29. Ooi G.T., Herington A.C., Covalent cross-linking of insulin-like= growth factor I to a specific inhi¬ bitor from human serum, Biochem. Biophys- Res. Commun. 1986: 137, 411. 30. Chochinov R.H., mariz I.K., Hajek A.S., Daughaday W.H., Characterization of a protein in mid-term human amniotic fluid which reacts in somatomedin-C radioreceptor assay, J. Clin. Endocrinol. Metab. 1977:44, 902.

Inventors: BRINKMAN AREND, DROP STENWERT LEONARD SEBASTIA, BRINKMAN, AREND, DROP, STENWERT, LEONARD, SEBASTIAN
Applicants: UNIV ERASMUS, ERASMUS UNIVERSITEIT
Application year: 1989
Main classification: C07K13
IPC codes: A61K38, A61P3, A61P17, A61P43, C07K1, C07K14, C12N15, C12P21, C12R1